$312.10
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
Goldman Sachs Initiates Praxis Precision Medicines at Buy With $447 Price Target
Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says
Overview
52-week range
$37
$367
83% of range
Avg surprise (last 3)
+3.5%
Avg reaction (last 2)
+2.2%
50% positive
Latest IV / EM
63%
EM ±14.4% · $310 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-3.20 | $-3.58 | +10.6% | +2.7% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-3.36 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $-3.31 | $-3.40 | +2.6% | — | — | earnings |
| Fri May 2, 2025 | Mar/2025 | $-3.29 | $-3.20 | -2.8% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.75 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.74 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.84 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.72 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-7.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | -$3.60 | -$3.31 | -8.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | — | $302,000 | $357,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-106M | — | $-78M | $-76M | $-75M | — | $-57M | $-37M |
| Net income | $-93M | — | $-74M | $-71M | $-69M | — | $-52M | $-33M |
| EPS (diluted) | $-3.20 | — | $-3.36 | $-3.31 | $-3.29 | — | $-2.75 | $-1.74 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $536M | $357M | $150M | $157M | $166M | $215M | $169M | $145M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $798M | $611M | $274M | $307M | $334M | $404M | $360M | $357M |
| Total assets | $1.46B | $938M | $396M | $453M | $479M | $483M | $416M | $441M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $50M | $60M | $53M | $49M | $40M | $38M | $34M | $22M |
| Total equity | $1.41B | $878M | $344M | $404M | $439M | $445M | $383M | $419M |